Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Pociredir · FTX-6058

Small molecule · developed by Fulcrum Therapeutics

Phase 2 Most advanced trial (none active)
FULC Developer
3 Registered trials

What is Pociredir?

Pociredir (FTX-6058) is an agent studied in healthy adult subjects and in patients with sickle cell disease.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
FTX-6058
Drug type
Small molecule
Therapy area
Hematology
Developer
Fulcrum Therapeutics (FULC)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2
UNII
BC2SSV7WMT

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07401823 Phase 2 Sickle Cell Disease Terminated FULC
NCT05169580 Phase 1 Sickle Cell Disease Completed FULC
NCT04586985 Phase 1 Healthy Adult Subjects Completed FULC

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Healthy Adult SubjectsSickle Cell AnemiaSickle Cell Disease

More from Fulcrum Therapeutics

Sources

Updated Nov 15, 2026. Something wrong or missing? Report it on the FULC page.

Follow FULC, the company behind Pociredir

See FULC's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

FULC catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.